Revvity Inc

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revvity Inc surpasses Q4 targets, eyes growth amid challenges

Revvity Inc delivered strong financial performance, exceeding targets and generating significant free cash flow, with a focus on organic growth and strategic M&A.
While facing challenges such as declining birth rates and COVID revenue impact, the company is leveraging opportunities in new product developments and global expansion.
Employee development initiatives and pricing strategies are key strengths, along with a positive outlook for the Life Science and Diagnostics business.
Overall, Revvity Inc's performance in 2022 sets a solid foundation for growth in 2023, supported by a diverse portfolio and strategic focus on innovation.

Revvity Inc reports strong Q1 earnings, eyes China growth

Revvity Inc's Q1 '23 earnings call highlighted strong financial performance, challenges in China Diagnostics, and opportunities for growth in the second half. The company is focused on maintaining operating margins, expanding product offerings, and capital deployment strategies to drive shareholder value.

Revvity Inc reports mixed Q2 performance, focuses on innovation

Revvity Inc's Q2 2023 performance reflected a mix of challenges and strengths, with a focus on innovation, cost-saving measures, and strategic investments to drive growth and profitability amidst market uncertainties.
While facing challenges in the Life Sciences segment, Revvity demonstrated strong performance in Diagnostics, showcasing its commitment to early disease detection and market leadership through innovation and new product launches.
The company's outlook includes opportunities to leverage its strengths, capture growth in key sectors and regions, and navigate challenges through strategic initiatives, aiming for sustained organic growth and operational excellence.

Revvity Inc reports Q3 growth amidst industry challenges and opportunities

Revvity Inc's Q3 performance showed resilience with revenue growth and cost actions, while facing challenges from industry headwinds and customer pressures.
The company's strengths lie in new initiatives driving growth, resilient business segments in China, and strong financial discipline with high free cash flow conversion.
Opportunities for Revvity include M&A activities, growth in key markets like China, strategic planning for future performance, and innovation through new product launches.
Despite challenges and uncertainties, Revvity Inc remains focused on navigating the current landscape, leveraging strengths, addressing challenges, and pursuing growth opportunities.

Revvity Inc reports Q4 earnings decline, eyes China growth

Revvity Inc's Q4 2023 earnings call highlighted a decline in organic revenue offset by strong performance in key segments. The company aims for 6-8% organic growth annually with a focus on margin expansion and expense management. Challenges include industry headwinds and margin pressure, while opportunities lie in portfolio differentiation and market growth in China.

Revvity Inc reports stable Q1 performance amidst growth opportunities

Revvity Inc's Q1 2024 performance showcased stability in market conversations and strong Diagnostics segment growth, despite a decline in organic revenue.
The company's focus on cost containment and innovation led to improved margins, strong free cash flow generation, and exceeding revenue expectations.
While facing challenges in pricing pressure and variable expenses, Revvity Inc remains optimistic about acquisitions, core reagents growth, and market opportunities for its products.

Revvity Inc (RVTY) reports strong Q2 earnings, eyes growth in China

Revvity Inc (RVTY) showcased resilience and operational efficiency in Q2 2024, with a strong focus on innovation and shareholder value. Despite challenges in China, the company anticipates growth opportunities in the Diagnostics segment.
With an increased adjusted EPS guidance, aggressive share repurchase plans, and emphasis on long-term value creation, Revvity Inc (RVTY) remains poised for sustained growth and profitability.

Revvity Inc excels in Q3 earnings, eyes growth in China

Revvity Inc's Q3 2024 earnings call reflects strong financial performance, strategic product launches, and lucrative contracts. While facing challenges in organic growth and market uncertainties, the company remains optimistic about future prospects, particularly in China.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity (NYSE: RVTY), today announced that it will release its second quarter 2023 financial results prior to market open on Tuesday, August 1, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on.

Revvity to Hold Earnings Call on Tuesday, August 1, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Today, in collaboration with single cell genomics company, Honeycomb Biotechnologies (“Honeycomb”), Revvity (NYSE: RVTY) announced the launch of a suite of new solutions and services that expand the frontiers of single cell biology: the HIVE™ CLX Single-Cell RNAseq Solution, BeeNetPLUS analysis workflow, and for single cell researchers based in the United States, a new HIVE CLX Service offering. The HIVE CLX Single-Cell RNAseq Solution offers higher density sing.

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.

Revvity (RVTY) Launches Single Solution for Drug Development

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY), announced the launch of its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development. The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity Signals Notebook, VitroVivo and Inventa applications into a single, r.

Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.

Revvity (RVTY) Launches New System for Autoimmune Diagnostics

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis. “Traditional.

Revvity's EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System

News for Revvity Inc Stock (RVTY)